FBX9 Antibody

Introduction to FBX9 Antibody

FBX9 Antibody is a polyclonal antibody targeting F-box protein 9 (FBXO9), a critical component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. FBXO9 regulates protein degradation via ubiquitination, influencing cellular processes such as mTOR signaling, cell growth, and survival . The antibody is widely used in research to study FBXO9’s role in diseases, including cancer, neurodegeneration, and sepsis, and to explore therapeutic potential .

Key Applications and Validations

FBX9 Antibody is validated for multiple techniques, enabling diverse experimental approaches:

Notable Findings:

• PACO48794 demonstrates specificity for human FBXO9 via IHC in pancreatic tissue and IF in HepG2 cells .

• 11161-1-AP (Proteintech) cross-reacts with mouse and rat samples, validated in WB and ELISA .

• FNAB03051 (R&D Mate) is optimized for large-scale experiments (100µg size) and validated in WB, IHC .

Antibody Comparison

Key Features:

• Purification: Protein G/Affinity-purified (>95% purity) .

• Storage: PBS with 50% glycerol, -20°C .

Mechanistic Insights

FBXO9 functions as a substrate-recognition subunit in SCF complexes, mediating ubiquitination of phosphorylated targets. Critical roles include:

1. mTOR Signaling Regulation:

   • SCF(FBXO9) degrades mTORC1-bound TTI1/TELO2 under growth factor deprivation, inactivating mTORC1 while activating mTORC2 .

   • Disruption of this balance is linked to cancer and metabolic disorders .

2. Protein Degradation:

   • Targets include PRMT4 (chromatin modulator) and PPARγ (adipogenesis regulator) .

3. Cellular Stress Response:

   • Regulates epithelial survival and innate immune response .

Disease Associations and Therapeutic Potential

Therapeutic Targets:

• Inhibiting FBXO9 may restore mTORC1 activity in metabolic disorders .

• Enhancing FBXO9-mediated degradation of oncogenic proteins could suppress cancer progression .